Gastroesophageal reflux disease is a common disease of digestive system. With the increase of domestic morbidity, the burden on the medical and health care system is correspondingly increased. The treatments of gastroesophageal reflux disease are mainly drug therapy and surgical treatment. With the increase in the number of selectable drugs and the emergence of new surgical techniques, it is particularly necessary to consider pharmacoeconomics of the plan while ensuring safety and effectiveness, especially in the context of the lack of overall medical and health resources in the country. The study of pharmacoeconomics considers different prevention, diag-nosis and treatment strategies from the perspective of economics, and provides reference for clinical treatment decision. The article re-viewed recent advances in pharmacoeconomics evaluations of gastroesophageal reflux disease.